11 results on '"Dibbens LM"'
Search Results
2. Reply.
- Author
-
Gardella E, Beniczky S, Møller RS, Becker F, Lemke JR, Syrbe S, Eiberg H, Bast T, Steinhoff B, Nürnberg P, Gellert P, Dahl HA, Weckhuysen S, Heron SE, Dibbens LM, Hjalgrim H, Lerche H, and Weber YG
- Published
- 2016
- Full Text
- View/download PDF
3. Exome-based analysis of cardiac arrhythmia, respiratory control, and epilepsy genes in sudden unexpected death in epilepsy.
- Author
-
Bagnall RD, Crompton DE, Petrovski S, Lam L, Cutmore C, Garry SI, Sadleir LG, Dibbens LM, Cairns A, Kivity S, Afawi Z, Regan BM, Duflou J, Berkovic SF, Scheffer IE, and Semsarian C
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Female, Genes, Dominant, Humans, Infant, Long QT Syndrome genetics, Male, Middle Aged, Mutation, Young Adult, Arrhythmias, Cardiac genetics, Death, Sudden etiology, Epilepsy genetics, Exome, Respiration Disorders genetics
- Abstract
Objective: The leading cause of epilepsy-related premature mortality is sudden unexpected death in epilepsy (SUDEP). The cause of SUDEP remains unknown. To search for genetic risk factors in SUDEP cases, we performed an exome-based analysis of rare variants., Methods: Demographic and clinical information of 61 SUDEP cases were collected. Exome sequencing and rare variant collapsing analysis with 2,936 control exomes were performed to test for genes enriched with damaging variants. Additionally, cardiac arrhythmia, respiratory control, and epilepsy genes were screened for variants with frequency of <0.1% and predicted to be pathogenic with multiple in silico tools., Results: The 61 SUDEP cases were categorized as definite SUDEP (n = 54), probable SUDEP (n = 5), and definite SUDEP plus (n = 2). We identified de novo mutations, previously reported pathogenic mutations, or candidate pathogenic variants in 28 of 61 (46%) cases. Four SUDEP cases (7%) had mutations in common genes responsible for the cardiac arrhythmia disease, long QT syndrome (LQTS). Nine cases (15%) had candidate pathogenic variants in dominant cardiac arrhythmia genes. Fifteen cases (25%) had mutations or candidate pathogenic variants in dominant epilepsy genes. No gene reached genome-wide significance with rare variant collapsing analysis; however, DEPDC5 (p = 0.00015) and KCNH2 (p = 0.0037) were among the top 30 genes, genome-wide., Interpretation: A sizeable proportion of SUDEP cases have clinically relevant mutations in cardiac arrhythmia and epilepsy genes. In cases with an LQTS gene mutation, SUDEP may occur as a result of a predictable and preventable cause. Understanding the genetic basis of SUDEP may inform cascade testing of at-risk family members., (© 2016 American Neurological Association.)
- Published
- 2016
- Full Text
- View/download PDF
4. Benign infantile seizures and paroxysmal dyskinesia caused by an SCN8A mutation.
- Author
-
Gardella E, Becker F, Møller RS, Schubert J, Lemke JR, Larsen LH, Eiberg H, Nothnagel M, Thiele H, Altmüller J, Syrbe S, Merkenschlager A, Bast T, Steinhoff B, Nürnberg P, Mang Y, Bakke Møller L, Gellert P, Heron SE, Dibbens LM, Weckhuysen S, Dahl HA, Biskup S, Tommerup N, Hjalgrim H, Lerche H, Beniczky S, and Weber YG
- Subjects
- Child, Child, Preschool, Chorea diagnosis, Epilepsy, Benign Neonatal diagnosis, Female, Humans, Male, Mutation genetics, Chorea genetics, Epilepsy, Benign Neonatal genetics, Genetic Predisposition to Disease genetics, NAV1.6 Voltage-Gated Sodium Channel genetics, Polymorphism, Single Nucleotide genetics
- Abstract
Objective: Benign familial infantile seizures (BFIS), paroxysmal kinesigenic dyskinesia (PKD), and their combination-known as infantile convulsions and paroxysmal choreoathetosis (ICCA)-are related autosomal dominant diseases. PRRT2 (proline-rich transmembrane protein 2 gene) has been identified as the major gene in all 3 conditions, found to be mutated in 80 to 90% of familial and 30 to 35% of sporadic cases., Methods: We searched for the genetic defect in PRRT2-negative, unrelated families with BFIS or ICCA using whole exome or targeted gene panel sequencing, and performed a detailed cliniconeurophysiological workup., Results: In 3 families with a total of 16 affected members, we identified the same, cosegregating heterozygous missense mutation (c.4447G>A; p.E1483K) in SCN8A, encoding a voltage-gated sodium channel. A founder effect was excluded by linkage analysis. All individuals except 1 had normal cognitive and motor milestones, neuroimaging, and interictal neurological status. Fifteen affected members presented with afebrile focal or generalized tonic-clonic seizures during the first to second year of life; 5 of them experienced single unprovoked seizures later on. One patient had seizures only at school age. All patients stayed otherwise seizure-free, most without medication. Interictal electroencephalogram (EEG) was normal in all cases but 2. Five of 16 patients developed additional brief paroxysmal episodes in puberty, either dystonic/dyskinetic or "shivering" attacks, triggered by stretching, motor initiation, or emotional stimuli. In 1 case, we recorded typical PKD spells by video-EEG-polygraphy, documenting a cortical involvement., Interpretation: Our study establishes SCN8A as a novel gene in which a recurrent mutation causes BFIS/ICCA, expanding the clinical-genetic spectrum of combined epileptic and dyskinetic syndromes., (© 2016 American Neurological Association.)
- Published
- 2016
- Full Text
- View/download PDF
5. Mutations in the mammalian target of rapamycin pathway regulators NPRL2 and NPRL3 cause focal epilepsy.
- Author
-
Ricos MG, Hodgson BL, Pippucci T, Saidin A, Ong YS, Heron SE, Licchetta L, Bisulli F, Bayly MA, Hughes J, Baldassari S, Palombo F, Santucci M, Meletti S, Berkovic SF, Rubboli G, Thomas PQ, Scheffer IE, Tinuper P, Geoghegan J, Schreiber AW, and Dibbens LM
- Subjects
- Exome, Gene Expression Profiling, Humans, Mechanistic Target of Rapamycin Complex 1, Mutation, Pedigree, Sequence Analysis, DNA, Epilepsies, Partial genetics, GTPase-Activating Proteins genetics, Multiprotein Complexes metabolism, Repressor Proteins genetics, Signal Transduction genetics, TOR Serine-Threonine Kinases metabolism, Tumor Suppressor Proteins genetics
- Abstract
Objective: Focal epilepsies are the most common form observed and have not generally been considered to be genetic in origin. Recently, we identified mutations in DEPDC5 as a cause of familial focal epilepsy. In this study, we investigated whether mutations in the mammalian target of rapamycin (mTOR) regulators, NPRL2 and NPRL3, also contribute to cases of focal epilepsy., Methods: We used targeted capture and next-generation sequencing to analyze 404 unrelated probands with focal epilepsy. We performed exome sequencing on two families with multiple members affected with focal epilepsy and linkage analysis on one of these., Results: In our cohort of 404 unrelated focal epilepsy patients, we identified five mutations in NPRL2 and five in NPRL3. Exome sequencing analysis of two families with focal epilepsy identified NPRL2 and NPRL3 as the top candidate-causative genes. Some patients had focal epilepsy associated with brain malformations. We also identified 18 new mutations in DEPDC5., Interpretation: We have identified NPRL2 and NPRL3 as two new focal epilepsy genes that also play a role in the mTOR-signaling pathway. Our findings show that mutations in GATOR1 complex genes are the most significant cause of familial focal epilepsy identified to date, including cases with brain malformations. It is possible that deregulation of cellular growth control plays a more important role in epilepsy than is currently recognized., (© 2015 American Neurological Association.)
- Published
- 2016
- Full Text
- View/download PDF
6. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations.
- Author
-
Scheffer IE, Heron SE, Regan BM, Mandelstam S, Crompton DE, Hodgson BL, Licchetta L, Provini F, Bisulli F, Vadlamudi L, Gecz J, Connelly A, Tinuper P, Ricos MG, Berkovic SF, and Dibbens LM
- Subjects
- Adult, Child, Female, GTPase-Activating Proteins, Humans, Male, Pedigree, Young Adult, Brain abnormalities, Epilepsies, Partial diagnosis, Epilepsies, Partial genetics, Mutation genetics, Repressor Proteins genetics, TOR Serine-Threonine Kinases genetics
- Abstract
We recently identified DEPDC5 as the gene for familial focal epilepsy with variable foci and found mutations in >10% of small families with nonlesional focal epilepsy. Here we show that DEPDC5 mutations are associated with both lesional and nonlesional epilepsies, even within the same family. DEPDC5-associated malformations include bottom-of-the-sulcus dysplasia (3 members from 2 families), and focal band heterotopia (1 individual). DEPDC5 negatively regulates the mammalian target of rapamycin (mTOR) pathway, which plays a key role in cell growth. The clinicoradiological phenotypes associated with DEPDC5 mutations share features with the archetypal mTORopathy, tuberous sclerosis, raising the possibility of therapies targeted to this pathway., (© 2014 American Neurological Association.)
- Published
- 2014
- Full Text
- View/download PDF
7. KCNT1 gain of function in 2 epilepsy phenotypes is reversed by quinidine.
- Author
-
Milligan CJ, Li M, Gazina EV, Heron SE, Nair U, Trager C, Reid CA, Venkat A, Younkin DP, Dlugos DJ, Petrovski S, Goldstein DB, Dibbens LM, Scheffer IE, Berkovic SF, and Petrou S
- Subjects
- Animals, Brain growth & development, Brain metabolism, Dose-Response Relationship, Drug, Electric Stimulation, Humans, Male, Mice, Mice, Inbred C57BL, Microinjections, Oocytes, Patch-Clamp Techniques, Potassium Channels, Sodium-Activated, Tetradecanoylphorbol Acetate analogs & derivatives, Tetradecanoylphorbol Acetate pharmacology, Time Factors, Xenopus laevis, Membrane Potentials drug effects, Membrane Potentials genetics, Mutation genetics, Nerve Tissue Proteins genetics, Potassium Channels genetics, Quinidine pharmacology, Voltage-Gated Sodium Channel Blockers pharmacology
- Abstract
Objective: Mutations in KCNT1 have been implicated in autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) and epilepsy of infancy with migrating focal seizures (EIMFS). More recently, a whole exome sequencing study of epileptic encephalopathies identified an additional de novo mutation in 1 proband with EIMFS. We aim to investigate the electrophysiological and pharmacological characteristics of hKCNT1 mutations and examine developmental expression levels., Methods: Here we use a Xenopus laevis oocyte-based automated 2-electrode voltage clamp assay. The effects of quinidine (100 and 300 μM) are also tested. Using quantitative reverse transcriptase polymerase chain reaction, the relative levels of mouse brain mKcnt1 mRNA expression are determined., Results: We demonstrate that KCNT1 mutations implicated in epilepsy cause a marked increase in function. Importantly, there is a significant group difference in gain of function between mutations associated with ADNFLE and EIMFS. Finally, exposure to quinidine significantly reduces this gain of function for all mutations studied., Interpretation: These results establish direction for a targeted therapy and potentially exemplify a translational paradigm for in vitro studies informing novel therapies in a neuropsychiatric disease., (© 2014 American Neurological Association.)
- Published
- 2014
- Full Text
- View/download PDF
8. A case of severe hearing loss in action myoclonus renal failure syndrome resulting from mutation in SCARB2.
- Author
-
Perandones C, Micheli FE, Pellene LA, Bayly MA, Berkovic SF, and Dibbens LM
- Subjects
- Adult, Audiometry, Pure-Tone, Auditory Pathways, Electroencephalography, Female, Hearing Loss genetics, Hearing Loss physiopathology, Humans, Mutation, Myoclonic Epilepsies, Progressive genetics, Myoclonic Epilepsies, Progressive physiopathology, Polymerase Chain Reaction, Hearing Loss etiology, Lysosomal Membrane Proteins genetics, Myoclonic Epilepsies, Progressive complications, Receptors, Scavenger genetics
- Published
- 2012
- Full Text
- View/download PDF
9. Augmented currents of an HCN2 variant in patients with febrile seizure syndromes.
- Author
-
Dibbens LM, Reid CA, Hodgson B, Thomas EA, Phillips AM, Gazina E, Cromer BA, Clarke AL, Baram TZ, Scheffer IE, Berkovic SF, and Petrou S
- Subjects
- Animals, Biophysics methods, Cyclic AMP pharmacology, Cyclic Nucleotide-Gated Cation Channels genetics, DNA Mutational Analysis methods, Electric Stimulation methods, Gene Frequency, Humans, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels, Membrane Potentials drug effects, Membrane Potentials genetics, Oocytes, Patch-Clamp Techniques methods, Potassium Channels genetics, Proline genetics, Transfection methods, Xenopus, Ion Channels genetics, Seizures, Febrile genetics, Sequence Deletion genetics
- Abstract
The genetic architecture of common epilepsies is largely unknown. HCNs are excellent epilepsy candidate genes because of their fundamental neurophysiological roles. Screening in subjects with febrile seizures and genetic epilepsy with febrile seizures plus revealed that 2.4% carried a common triple proline deletion (delPPP) in HCN2 that was seen in only 0.2% of blood bank controls. Currents generated by mutant HCN2 channels were approximately 35% larger than those of controls; an effect revealed using automated electrophysiology and an appropriately powered sample size. This is the first association of HCN2 and familial epilepsy, demonstrating gain of function of HCN2 current as a potential contributor to polygenic epilepsy.
- Published
- 2010
- Full Text
- View/download PDF
10. SCARB2 mutations in progressive myoclonus epilepsy (PME) without renal failure.
- Author
-
Dibbens LM, Michelucci R, Gambardella A, Andermann F, Rubboli G, Bayly MA, Joensuu T, Vears DF, Franceschetti S, Canafoglia L, Wallace R, Bassuk AG, Power DA, Tassinari CA, Andermann E, Lehesjoki AE, and Berkovic SF
- Subjects
- Adolescent, Adult, Diagnosis, Differential, Female, Follow-Up Studies, Humans, Male, Polymerase Chain Reaction, RNA Splicing, Renal Insufficiency diagnosis, Unverricht-Lundborg Syndrome diagnosis, Unverricht-Lundborg Syndrome genetics, Young Adult, Lysosomal Membrane Proteins genetics, Mutation, Myoclonic Epilepsies, Progressive diagnosis, Myoclonic Epilepsies, Progressive genetics, Receptors, Scavenger genetics, Renal Insufficiency genetics
- Abstract
Objective: Mutations in SCARB2 were recently described as causing action myoclonus renal failure syndrome (AMRF). We hypothesized that mutations in SCARB2 might account for unsolved cases of progressive myoclonus epilepsy (PME) without renal impairment, especially those resembling Unverricht-Lundborg disease (ULD). Additionally, we searched for mutations in the PRICKLE1 gene, newly recognized as a cause of PME mimicking ULD., Methods: We reviewed cases of PME referred for diagnosis over two decades in which a molecular diagnosis had not been reached. Patients were classified according to age of onset, clinical pattern, and associated neurological signs into "ULD-like" and "not ULD-like." After exclusion of mutations in cystatin B (CSTB), DNA was examined for sequence variation in SCARB2 and PRICKLE1., Results: Of 71 cases evaluated, 41 were "ULD-like" and five had SCARB2 mutations. None of 30 "not ULD-like" cases were positive. The five patients with SCARB2 mutations had onset between 14 and 26 years of age, with no evidence of renal failure during 5.5 to 15 years of follow-up; four were followed until death. One living patient had slight proteinuria. A subset of 25 cases were sequenced for PRICKLE1 and no mutations were found., Interpretation: Mutations in SCARB2 are an important cause of hitherto unsolved cases of PME resembling ULD at onset. SCARB2 should be evaluated even in the absence of renal involvement. Onset is in teenage or young adult life. Molecular diagnosis is important for counseling the patient and family, particularly as the prognosis is worse than classical ULD.
- Published
- 2009
- Full Text
- View/download PDF
11. SCN1A mutations and epilepsy.
- Author
-
Mulley JC, Scheffer IE, Petrou S, Dibbens LM, Berkovic SF, and Harkin LA
- Subjects
- Alternative Splicing genetics, Humans, Molecular Sequence Data, NAV1.1 Voltage-Gated Sodium Channel, Sodium Channels metabolism, Epilepsy genetics, Mutation genetics, Nerve Tissue Proteins genetics, Sodium Channels genetics
- Abstract
SCN1A is part of the SCN1A-SCN2A-SCN3A gene cluster on chromosome 2q24 that encodes for alpha pore forming subunits of sodium channels. The 26 exons of SCN1A are spread over 100 kb of genomic DNA. Genetic defects in the coding sequence lead to generalized epilepsy with febrile seizures plus (GEFS+) and a range of childhood epileptic encephalopathies of varied severity (e.g., SMEI). All published mutations are collated. More than 100 novel mutations are spread throughout the gene with the more debilitating usually de novo. Some clustering of mutations is observed in the C-terminus and the loops between segments 5 and 6 of the first three domains of the protein. Functional studies so far show no consistent relationship between changes to channel properties and clinical phenotype. Of all the known epilepsy genes SCN1A is currently the most clinically relevant, with the largest number of epilepsy related mutations so far characterized.
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.